Hoth Therapeutics to resume at-the-market stock sales under H.C. Wainwright agreement

• Hoth Therapeutics plans to resume sales of common stock under its at-the-market offering agreement with H.C. Wainwright.
• Company will file a new prospectus supplement tied to its effective Form S-3 registration statement.
• Prior prospectus supplement for the program was suspended and terminated, while sales agreement remained in effect.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-044741), on April 16, 2026, and is solely responsible for the information contained therein.